ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus(MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. Source
No articles found.
HMS advances the healthcare system by helping healthcare organizations reduce cost...
HMS advances the healthcare system by helping h...
ConforMIS is a medical technology company that uses its proprietary iFitÂŽ Image-t...
ConforMIS is a medical technology company that ...
Heska Corporation (NASDAQ: HSKA â News) manufactures, develops and sells advance...
Heska Corporation (NASDAQ: HSKA â News) manuf...
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet pa...
OPKO Health, Inc. is a diversified healthcare c...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, de...
Entasis is a clinical-stage biopharmaceutical c...
Join the National Investor Network and get the latest information with your interests in mind.